109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
通过群体药代动力学建模与模拟优化拉莫三嗪在围孕期癫痫中的剂量
Authors Huo J , Liu Y, Yang J, Chen M, Yang L, Wang L, Zhang D, Liu T, Gao W, Dai H , Mei S , Zhao Z
Received 20 May 2025
Accepted for publication 3 November 2025
Published 20 November 2025 Volume 2025:19 Pages 10243—10258
DOI https://doi.org/10.2147/DDDT.S541597
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Professor Tamer Ibrahim
Jiping Huo,1,2,* Yilin Liu,3,* Jiayu Yang,1,2,* Meng Chen,4,* Li Yang,1 Lijun Wang,5 Dongjie Zhang,1 Tongtong Liu,1 Wanli Gao,5 Haibin Dai,4 Shenghui Mei,1,2 Zhigang Zhao1,2
1Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, People’s Republic of China; 2Department of Clinical Pharmacology, College of Pharmaceutical Sciences, Capital Medical University, Beijing, 100045, People’s Republic of China; 3National Institute for Drug Clinical Trial, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, People’s Republic of China; 4Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China; 5Department of Gynaecology and Obstetrics, Beijing Tiantan Hospital, Capital Medical University, Beijing, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Shenghui Mei, Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 119 Nansihuan West Road, Fengtai District, Beijing, People’s Republic of China, Email meishenghui1983@126.com Zhigang Zhao, Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 119 Nansihuan West Road, Fengtai District, Beijing, People’s Republic of China, Email ttyyzzg1022@126.com
Purpose: Lamotrigine demonstrates substantial interindividual pharmacokinetic variability during pregnancy, though the underlying mechanisms remain incompletely understood. The study aimed to develop a population pharmacokinetic model of lamotrigine in Chinese epileptic patients during the peripregnancy period, in order to identify the key influencing factors and thereby assist in providing a solution for the individualized administration of lamotrigine.
Methods: One hundred and twenty-eight perigestational epilepsy patients (293 plasma concentrations) from two Chinese hospitals between January 1, 2015 and May 31, 2024 were enrolled in the study. A nonlinear mixed-effects model was developed using Phoenix NLME™ (v8.3) with stepwise covariate selection. Model validation encompassed goodness-of-fit analysis, bootstrap analysis (n = 1000), prediction-corrected visual predictive checks, and normalized prediction distribution error evaluation. Optimal dosing regimens were derived through Monte Carlo simulations accounting for gestational/postpartum physiological changes.
Results: A one - compartment model combined with an additive and proportional error model was employed to characterize the pharmacokinetics of lamotrigine. Each factor’s impact on CL/F was systematically examined using a stepwise approach, resulting in the establishment of the final model: . CL/F was identified as the primary pharmacokinetic parameter, serving as the main outcome measure and foundational basis for dosing recommendations. The model demonstrated satisfactory accuracy and commendable predictability. LTG CL/F increased significantly from 5 weeks of gestation, with CL/F in stages 2, 3, and 4 being 131%, 193%, and 199% of stage 1 (< 5 weeks), respectively, and declining sharply to 68% of stage 1 postpartum.
Conclusion: The CL/F of lamotrigine was found to be increased significantly from 5 weeks of gestation and dropped sharply postpartum. Weight, pregnancy stage, and co-administration with valproic acid were identified as significant influencing factors. The internal verification results of the model were generally satisfactory, however, prospective multicenter cohorts incorporating larger-scale external datasets are imperative to establish robust generalizability, ultimately enabling precise personalized dose optimization strategies for peripregnancy epileptic patients.
Keywords: lamotrigine, peripregnancy, epilepsy, population pharmacokinetic model, nonlinear mixed effects modeling
1Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, People’s Republic of China; 2Department of Clinical Pharmacology, College of Pharmaceutical Sciences, Capital Medical University, Beijing, 100045, People’s Republic of China; 3National Institute for Drug Clinical Trial, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, People’s Republic of China; 4Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China; 5Department of Gynaecology and Obstetrics, Beijing Tiantan Hospital, Capital Medical University, Beijing, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Shenghui Mei, Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 119 Nansihuan West Road, Fengtai District, Beijing, People’s Republic of China, Email meishenghui1983@126.com Zhigang Zhao, Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 119 Nansihuan West Road, Fengtai District, Beijing, People’s Republic of China, Email ttyyzzg1022@126.com
Purpose: Lamotrigine demonstrates substantial interindividual pharmacokinetic variability during pregnancy, though the underlying mechanisms remain incompletely understood. The study aimed to develop a population pharmacokinetic model of lamotrigine in Chinese epileptic patients during the peripregnancy period, in order to identify the key influencing factors and thereby assist in providing a solution for the individualized administration of lamotrigine.
Methods: One hundred and twenty-eight perigestational epilepsy patients (293 plasma concentrations) from two Chinese hospitals between January 1, 2015 and May 31, 2024 were enrolled in the study. A nonlinear mixed-effects model was developed using Phoenix NLME™ (v8.3) with stepwise covariate selection. Model validation encompassed goodness-of-fit analysis, bootstrap analysis (n = 1000), prediction-corrected visual predictive checks, and normalized prediction distribution error evaluation. Optimal dosing regimens were derived through Monte Carlo simulations accounting for gestational/postpartum physiological changes.
Results: A one - compartment model combined with an additive and proportional error model was employed to characterize the pharmacokinetics of lamotrigine. Each factor’s impact on CL/F was systematically examined using a stepwise approach, resulting in the establishment of the final model: . CL/F was identified as the primary pharmacokinetic parameter, serving as the main outcome measure and foundational basis for dosing recommendations. The model demonstrated satisfactory accuracy and commendable predictability. LTG CL/F increased significantly from 5 weeks of gestation, with CL/F in stages 2, 3, and 4 being 131%, 193%, and 199% of stage 1 (< 5 weeks), respectively, and declining sharply to 68% of stage 1 postpartum.
Conclusion: The CL/F of lamotrigine was found to be increased significantly from 5 weeks of gestation and dropped sharply postpartum. Weight, pregnancy stage, and co-administration with valproic acid were identified as significant influencing factors. The internal verification results of the model were generally satisfactory, however, prospective multicenter cohorts incorporating larger-scale external datasets are imperative to establish robust generalizability, ultimately enabling precise personalized dose optimization strategies for peripregnancy epileptic patients.
Keywords: lamotrigine, peripregnancy, epilepsy, population pharmacokinetic model, nonlinear mixed effects modeling